Head and Neck Diseases by Alexandros G.Sfakianakis: Cardiotoxicity risk with bortezomib versus lenalidomide for treatment of multiple myeloma: A propensity matched study of 1,790 patients.

Παρασκευή 8 Δεκεμβρίου 2017

Cardiotoxicity risk with bortezomib versus lenalidomide for treatment of multiple myeloma: A propensity matched study of 1,790 patients.

http:--media.wiley.com-assets-7315-19-Wi

Related Articles

Cardiotoxicity risk with bortezomib versus lenalidomide for treatment of multiple myeloma: A propensity matched study of 1,790 patients.

Am J Hematol. 2017 02;92(2):E15-E17

Authors: Reneau JC, Asante D, van Houten H, Sangaralingham LR, Buadi FK, Lerman A, Herrmann J

PMID: 27813147 [PubMed - indexed for MEDLINE]

http://ift.tt/2j86ccW

Δεν υπάρχουν σχόλια:

Δημοσίευση σχολίου

Εγγραφή σε: Σχόλια ανάρτησης (Atom)